Tick-borne Encephalitis Vaccine
On August 13, 2021, the Food and Drug Administration approved a tick-borne encephalitis (TBE) vaccine, TICOVAC™, manufactured by Pfizer. The vaccine is an inactivated vaccine that has been licensed and used in Europe for about 20 years. The vaccine has both pediatric and adult formulations and is the only one currently licensed in the United States. An Advisory Committee on Immunization Practices (ACIP) Work Group was formed in 2020 to discuss the use of TBE vaccine in children and adults traveling to or residing in areas at risk and in laboratory workers. The Work Group is currently reviewing the epidemiology of TBE among travelers and laboratory workers, and data on the safety and effectiveness of the TBE vaccine. The Work Group is developing evidence-based recommendations for consideration by ACIP which will likely be approved in 2022. Information on TBE can be found here. Updates on vaccine recommendations can be found here.